MTHFR testing commonly reports two widespread gene variants, C677T and A1298C. These variants can modestly change activity of the methylenetetrahydrofolate reductase enzyme, which participates in folate metabolism and the conversion of homocysteine to methionine. They are often marketed as explanations for blood clots, miscarriage, infertility, heart disease, fatigue, psychiatric symptoms, or a supposed inability to use folic acid. For most people, those claims go far beyond the evidence. Common MTHFR variants are not considered inherited thrombophilias, and major professional guidance does not recommend using them to evaluate venous blood clots or recurrent pregnancy loss. When homocysteine is elevated, the level itself and treatable causes such as vitamin B12 or folate deficiency, kidney disease, thyroid disease, medicines, and lifestyle factors are usually more clinically useful than the genotype. Rare severe MTHFR deficiency is a different, serious metabolic disorder and should not be confused with C677T or A1298C results.
- C677T and A1298C are common polymorphisms, not automatically disease-causing “mutations.”
- An MTHFR result does not diagnose a clotting disorder or explain most miscarriages.
- People with common MTHFR variants can process folic acid; standard pregnancy guidance still applies.
- Homocysteine should be interpreted directly and in context rather than inferred from genotype.
- Rare biallelic MTHFR deficiency is clinically distinct from routine consumer testing.
Table of Contents
- What the MTHFR gene does
- C677T and A1298C results
- Homocysteine and clinical context
- Blood clots, heart risk, and stroke
- Pregnancy, fertility, and folic acid
- When testing may or may not help
- Rare severe MTHFR deficiency
- What to do with a result
What the MTHFR gene does
MTHFR provides instructions for an enzyme called methylenetetrahydrofolate reductase. The enzyme helps convert one folate form into 5-methyltetrahydrofolate, which donates a methyl group during conversion of homocysteine to methionine. Methionine then contributes to production of S-adenosylmethionine, a molecule used in many methylation reactions. This pathway depends on adequate folate, vitamin B12, vitamin B6, riboflavin, and normal function of other enzymes, organs, and transport systems.
The pathway is important, but that does not mean every common variation in MTHFR creates disease. Human genes naturally differ among individuals. C677T and A1298C are common polymorphisms found in healthy people worldwide, with frequencies that vary by ancestry and population. Laboratories may describe them using DNA notation such as c.665C>T and c.1286A>C, protein notation, or older names. A result can therefore look more alarming than its clinical effect warrants.
The C677T variant can reduce enzyme activity, especially when a person has two T copies. The effect on blood homocysteine is most apparent when folate status is low. In populations with folic-acid fortification and adequate vitamin intake, the average difference is usually modest. A1298C generally has a smaller effect and, by itself, often does not substantially raise homocysteine. Compound heterozygosity means one C677T copy and one A1298C copy, usually on opposite gene copies; it is not equivalent to having two copies of C677T and is not a diagnosis of severe deficiency.
Folate metabolism is sometimes oversimplified online as a single “methylation switch.” In reality, one-carbon metabolism is a network with multiple inputs, enzymes, feedback loops, and tissue-specific demands. Symptoms such as fatigue, anxiety, headache, brain fog, or poor sleep are nonspecific and cannot be attributed to an MTHFR genotype without a separate clinical evaluation. A common variant may influence a laboratory value slightly while still providing little useful information about an individual symptom.
The word “mutation” is also frequently misused. In clinical genetics, a variant is classified according to evidence and context. C677T and A1298C are common risk modifiers, not the same as rare pathogenic variants that cause severe autosomal recessive MTHFR deficiency. The distinction matters because management, recurrence risk, and urgency are entirely different.
C677T and A1298C results
For C677T, a report may show CC, CT, or TT. CC means no T copy at that position, CT means one T copy, and TT means two T copies. CT is often called heterozygous and TT homozygous. Neither result alone diagnoses an illness. TT is associated with lower average enzyme activity and may be associated with higher homocysteine when folate intake is inadequate, but many people with TT have normal homocysteine and no related clinical problem.
For A1298C, results are commonly AA, AC, or CC. AC means one C copy and CC two. A1298C usually has less influence on enzyme thermolability and homocysteine than C677T. A report stating “homozygous A1298C” can sound severe, yet the result generally does not establish a clinically important folate-processing disorder.
A compound heterozygous result usually means one C677T copy and one A1298C copy. Some commercial interpretations describe this as two “mutations” and assign broad health risks. That framing is misleading. The variants’ positions, whether they are on opposite gene copies, folate status, and measured homocysteine all matter, and the genotype still does not constitute a thrombophilia diagnosis.
Direct-to-consumer tests may use raw single-nucleotide polymorphism data rather than a validated clinical assay. Strand orientation, chip version, imputation, and data-conversion errors can produce confusion. If a result is being considered for a consequential medical decision, it should be confirmed in an appropriately accredited clinical laboratory. Confirmation, however, does not make a low-utility test clinically necessary; it only verifies the genotype.
A negative result for C677T and A1298C does not guarantee normal homocysteine. Vitamin deficiency, kidney impairment, hypothyroidism, smoking, heavy alcohol use, age, some medicines, and rare metabolic disorders can raise it. Conversely, a positive common-variant result does not guarantee elevation. The genotype is therefore a poor substitute for measuring the biomarker when a clinician has a valid reason to assess it.
Results may appear incidentally on broad carrier, cardiovascular, nutrition, or pharmacogenomic panels. The appropriate response is usually to interpret them conservatively. They should not be converted into a long list of diagnoses, used to label family members as having a clotting disorder, or become the basis for indefinite supplements or anticoagulants.
Homocysteine and clinical context
Homocysteine is an amino acid intermediate measured in blood, usually as total plasma homocysteine. Laboratories have different reference ranges, and fasting status, recent illness, sample handling, age, sex, pregnancy, and kidney function can affect results. A mildly elevated value should be confirmed and interpreted rather than treated as proof of an MTHFR problem.
Common acquired causes include low vitamin B12, folate, or vitamin B6 status; reduced kidney function; hypothyroidism; smoking; high alcohol intake; and certain drugs. Metformin and acid-suppressing medicines can contribute indirectly through vitamin B12 deficiency in some people. Methotrexate, some antiseizure medicines, and other agents can affect folate pathways. Dietary restriction, malabsorption, celiac disease, inflammatory bowel disease, bariatric surgery, and pernicious anemia may also be relevant.
Vitamin B12 deserves special attention because folic acid can improve anemia while neurologic injury from B12 deficiency progresses. Evaluation may include a complete blood count, serum B12, methylmalonic acid in selected cases, folate, creatinine or estimated glomerular filtration rate, thyroid testing, and medication review. The exact workup should match the degree of elevation and clinical circumstances.
Mild or moderate hyperhomocysteinemia is associated observationally with vascular disease, but association is not the same as causation. Randomized trials that lowered homocysteine with B vitamins did not consistently produce the broad cardiovascular benefits once expected. Treatment should therefore focus on correcting true deficiencies and managing established cardiovascular risks rather than chasing a target based solely on genotype.
Markedly elevated homocysteine, especially in a child or young adult with developmental, neurologic, psychiatric, eye, skeletal, or thrombotic findings, raises a different concern. Classical homocystinuria due to CBS deficiency and remethylation disorders can cause very high levels and require urgent metabolic evaluation. These conditions cannot be ruled in or out by a routine C677T/A1298C test.
Repeat testing may be reasonable after correcting a deficiency or changing a contributing medicine, but routine serial monitoring in an asymptomatic person with a common MTHFR variant is usually unnecessary. A clinician should decide whether the number will change management. The goal is to identify a treatable cause, not to normalize every small laboratory variation.
Blood clots, heart risk, and stroke
MTHFR C677T and A1298C are not considered clinically meaningful inherited thrombophilias. They should not be grouped with Factor V Leiden, the prothrombin G20210A variant, antithrombin deficiency, protein C deficiency, or protein S deficiency. Professional guidance has repeatedly advised against ordering common MTHFR genotyping as part of a thrombosis evaluation because it does not meaningfully predict venous thromboembolism or guide anticoagulation.
This distinction prevents harm. A person incorrectly labeled with “MTHFR clotting disorder” may be exposed to unnecessary aspirin, heparin, or long-term anticoagulation, each of which can cause bleeding. The label may also influence contraception, pregnancy management, surgery planning, travel anxiety, or insurance decisions without evidence of benefit. A thrombophilia evaluation should be driven by the personal clot history, age at the event, provoking factors, family history, and whether a result would change care.
For someone who has had deep-vein thrombosis or pulmonary embolism, duration of anticoagulation is generally based on whether the event was provoked, recurrence risk, bleeding risk, cancer, antiphospholipid syndrome, and other clinical factors. An MTHFR common-variant result should not extend or shorten treatment. It also does not justify testing healthy relatives as though they inherited a high-risk thrombophilia.
Arterial events such as heart attack and ischemic stroke have different mechanisms from most venous clots. Blood pressure, LDL cholesterol, diabetes, smoking, age, atrial fibrillation, and established vascular disease carry far greater actionable value. Even when C677T is statistically associated with a small change in risk in a particular population, the result does not replace standard prevention. Treatment should target measured risk factors.
If homocysteine is elevated after a stroke or other vascular event, clinicians may assess nutritional deficiencies and renal function. Correcting a deficiency is appropriate for general health, but the MTHFR genotype itself does not identify the cause with enough specificity. Genetic testing for prothrombin G20210A or other thrombophilias also has limited, situation-dependent indications and should not be ordered as an indiscriminate panel.
A strong family history of early thrombosis warrants a careful hematology assessment, not automatic MTHFR testing. The family pattern may reflect a different thrombophilia, antiphospholipid syndrome, cancer, shared environmental risks, or an unknown cause. The test chosen should answer a defined question and have a plausible path to changing management.
Pregnancy, fertility, and folic acid
Common MTHFR variants are frequently blamed for infertility, implantation failure, recurrent miscarriage, preeclampsia, placental abruption, fetal growth restriction, and stillbirth. Although individual association studies and meta-analyses have reported variable relationships, the total evidence has not established routine MTHFR testing as a useful evaluation for these outcomes. Major obstetric and genetics recommendations do not support using C677T or A1298C to diagnose a cause of recurrent pregnancy loss.
Pregnancy loss has many possible causes, including chromosomal abnormalities, uterine factors, antiphospholipid syndrome, endocrine disease, parental chromosome rearrangements, and age-related risk. Many losses remain unexplained even after appropriate evaluation. An MTHFR result can create false certainty and divert attention from evidence-based assessment.
People who can become pregnant should follow standard folic-acid recommendations regardless of MTHFR genotype. In the United States, public-health guidance recommends 400 micrograms of folic acid daily for people capable of becoming pregnant to help prevent neural-tube defects. Folic acid is the form proven to prevent these defects, and people with C677T or A1298C can process it. The claim that they must avoid folic acid and use only methylfolate is not supported by public-health evidence.
Some individuals need a higher folic-acid dose because of a previous neural-tube-defect-affected pregnancy, certain antiseizure medicines, malabsorption, or another clinical factor. That decision should be made with a clinician; it is not based simply on a common MTHFR result. More is not always better, and high-dose supplementation can mask vitamin B12 deficiency or interact with treatment plans.
Methylfolate is a biologically active folate form and may be used in some supplements or specific clinical settings, but it has not replaced folic acid as the evidence-based standard for neural-tube-defect prevention. Marketing language about “toxic folic acid” or universal “methylation blockage” is misleading. Product quality and dose also vary.
An MTHFR result does not by itself justify aspirin, low-molecular-weight heparin, progesterone, or intensified pregnancy surveillance. These treatments have specific indications and risks. If antiphospholipid syndrome, a prior venous clot, or another established condition is present, management should follow that diagnosis—not the MTHFR genotype.
When testing may or may not help
Routine testing for C677T and A1298C usually does not help in the evaluation of thrombosis, recurrent miscarriage, infertility, cardiovascular risk, nonspecific symptoms, or decisions about standard folic-acid supplementation. The result rarely changes evidence-based management. In many settings, the best pretest question is simple: what will be done differently for each possible genotype? If the answer is nothing, testing is unlikely to add value.
Measurement of homocysteine itself is also not a universal screening test. It may be useful when a clinician suspects a nutritional deficiency, malabsorption, severe or unexplained elevation, a remethylation disorder, classical homocystinuria, or another specific metabolic problem. Testing should be paired with a plan to investigate the cause.
Rare situations involving medication response may require specialized interpretation. MTHFR and folate-pathway variants have been studied in relation to methotrexate toxicity and efficacy, but associations are inconsistent and depend on disease, dose, treatment protocol, ancestry, and other genes. A common MTHFR result should not prompt a patient to stop methotrexate or alter cancer, rheumatology, or immunology treatment without the prescribing team.
Broad genomic sequencing can incidentally detect rare MTHFR variants. When the phenotype suggests severe enzyme deficiency, clinical laboratories assess variant pathogenicity, inheritance, biochemical findings, and whether two disease-causing variants are present. That is fundamentally different from ordering a two-polymorphism wellness test.
Testing may have personal meaning for someone who already has raw data, but personal interest should not be confused with medical necessity. Genetic counseling can help separate a benign common genotype from a rare disease-causing result and correct misconceptions that have influenced diet, pregnancy plans, or medication use.
Clinicians should also consider opportunity cost. Money and attention spent on low-value MTHFR testing may be better directed toward blood pressure control, lipid testing, diabetes prevention, smoking cessation, evidence-based prenatal care, vitamin B12 assessment, or evaluation of an actual clotting disorder. A test is useful only when its result improves a decision.
Rare severe MTHFR deficiency
Severe MTHFR deficiency is a rare autosomal recessive disorder caused by biallelic pathogenic variants that markedly impair enzyme function. It is not defined by having TT at C677T, CC at A1298C, or both common variants. Affected individuals usually have biochemical evidence of defective remethylation, including elevated homocysteine and low methionine, and may present in infancy, childhood, or later life.
Possible features include developmental delay, intellectual disability, hypotonia, seizures, movement disorders, psychiatric symptoms, encephalopathy, abnormal gait, lens or eye findings in the differential diagnosis, and thromboembolic events. Presentation can be variable, so diagnosis depends on biochemical and molecular evaluation rather than one symptom. Newborn screening may not identify every remethylation disorder, depending on the program and markers used.
When severe disease is suspected, clinicians may measure total homocysteine, methionine, methylmalonic acid, vitamin levels, and other metabolites, then order a comprehensive gene panel or sequencing with deletion and duplication analysis. Finding two pathogenic MTHFR variants in trans supports the diagnosis. Parental testing can confirm inheritance. A single common polymorphism does not explain a severe biochemical phenotype.
Treatment is directed by a metabolic specialist and may include betaine to support remethylation, folate-related therapies, vitamin B12 or other cofactors, methionine management, and treatment of complications. Early recognition can matter, but regimens are individualized. Consumer supplement protocols are not substitutes for metabolic care.
Because the disorder is recessive, parents of an affected person are usually carriers. Each full sibling has a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of inheriting neither familial pathogenic variant. Carrier relatives generally do not have the severe disorder. Reproductive counseling and targeted familial testing become appropriate only after the causative variants are established.
The shared gene name causes avoidable confusion. A useful report should state whether it concerns common polymorphisms with limited clinical utility or rare pathogenic variants associated with MTHFR deficiency. The biochemical pattern and phenotype usually make the distinction clear to specialists.
What to do with a result
First, identify exactly what was tested. A report limited to C677T and A1298C does not sequence the entire MTHFR gene and cannot diagnose or exclude rare severe deficiency. Confirm the notation, zygosity, laboratory method, and whether the result came from a clinical laboratory or consumer raw data.
Second, match the result to the actual clinical question. For clotting, ask whether there was a documented deep-vein thrombosis, pulmonary embolism, or unusual-site thrombosis and whether it was provoked. For pregnancy loss, ask whether evidence-based evaluation has been completed. For fatigue or neurologic symptoms, pursue a general medical assessment rather than assuming a methylation cause.
Third, review measured laboratory values. If homocysteine is normal, a common variant usually requires no action. If it is elevated, investigate vitamin B12 and folate status, kidney function, thyroid disease, medications, smoking, alcohol, nutrition, and malabsorption. Severe elevation or a suggestive childhood phenotype warrants metabolic referral.
Fourth, avoid treatment based solely on the genotype. Do not start or continue aspirin, anticoagulation, very high-dose folate, or multiple supplements merely because a report says “heterozygous,” “homozygous,” or “compound heterozygous.” Supplements can cause adverse effects, interact with medicines, and obscure a diagnosis. Standard folic acid remains appropriate for neural-tube-defect prevention.
Fifth, correct the medical record if it inaccurately lists “MTHFR thrombophilia.” A more precise entry might state “common MTHFR polymorphism; not a clinically significant inherited thrombophilia.” This can prevent unnecessary treatment during surgery, pregnancy, or future clot evaluations.
Finally, ask whether any follow-up result would change care. Common variants do not generally warrant family cascade testing or repeated genotyping. A rare pathogenic result, markedly abnormal biochemistry, or a phenotype suggestive of a remethylation disorder does warrant genetics and metabolic expertise. The most useful interpretation is often reassuring: common MTHFR results are widespread and usually do not require special medical management.
References
- MTHFR Gene Variant and Folic Acid Facts. 2025. Centers for Disease Control and Prevention public-health guidance.
- Thrombophilia testing: when is it appropriate and when is it not?. 2025. Peer-reviewed clinical review.
- Thrombophilia testing: A British Society for Haematology guideline. 2022. Professional clinical guideline.
- Inherited Thrombophilias in Pregnancy. 2018, reaffirmed guidance. American College of Obstetricians and Gynecologists practice bulletin.
- ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. 2013, with later addendum. Professional genetics guideline.
- Homocystinurias. Updated GeneReviews chapter. Expert clinical review.
Disclaimer
This article provides general education and does not replace individualized medical care, laboratory interpretation, prenatal advice, or genetic counseling. Do not start or stop folate, aspirin, anticoagulation, methotrexate, or another treatment because of an MTHFR result without consulting the relevant clinician. Seek urgent care for symptoms of a blood clot, stroke, severe neurologic change, or another medical emergency.
